Radiation Countermeasures (USUHS)
Abstract
Radiation Countermeasures (USU): For the Uniformed Services University of the Health Sciences (USU), this program supports applied research for advanced development of biomedical strategies to prevent and treat health consequences from exposure to ionizing radiation. It capitalizes on findings under PE 0602787HP, Medical Technology, and from industry and academia to advance novel medical countermeasures into and through pre-clinical studies toward newly licensed products. Program objectives focus on preventing or mitigating the health consequences from exposures to ionizing radiation alone or in combination with other injuries, in the context of probable threats to US forces in current tactical, humanitarian and counterterrorism mission environments. Findings from basic and developmental research are integrated into highly focused advanced technology development studies yielding protective and therapeutic strategies. FY 2018 Plans: FY 2018 plans to continue development studies in animal models for acute radiation syndrome drug discovery and development to further characterize the efficacy and safety profile of promising drug substances and products and to elucidate their mechanism of action as radiation countermeasures. Radiation countermeasure candidates such CDX-301, TPOm, PrC-210, BBT059 at various stages of preclinical development will be evaluated for advances towards clinical studies and application. FY 2018 Accomplishments: -Evaluated dose-dependence of radioprotective efficacy of BMT-LIPO-GT3, a new and proprietary formulation of gamma-tocotrienol (GT3), in mice. -Mice experimentation conducted with a radioprotectant drug, amifostine and a PARP inhibitor, Talazoparib, for metabololomic and lipidomic studies to establish their pharmacological profiles and potential impact on radiation effects.
Document Details
- Document Type
- Accomplishment
- Publication Date
- Oct 01, 2020
- Source ID
- 943f02d3e0f9cccb205f77a4046ccb21